Press Release

ASKA Pharmaceutical Holdings Co., Ltd.

Licensing Agreement on Relugolix Combination Tablet
in Women's Health Indications

TOKYO, September 27th, 2021 – ASKA Pharmaceutical Co., Ltd. (Headquarter: Minato-ku, Tokyo/Representative Director: Sohta Yamaguchi, "ASKA"), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (Headquarter: Minato-ku, Tokyo/Representative Director: Takashi Yamaguchi), announced today that ASKA entered into a license agreement for exclusive development and commercialization for uterine fibroids for Japan of Takeda Pharmaceutical Company Limited "Takeda" - owned relugolix (generic name) combination tablet (relugolix, estradiol-INN, norethindrone acetate-INN, and development codes: TAK-385).

Relugolix is a gonadotropin-releasing hormone (gonadotropin-releasing hormone :GnRH) receptor antagonist developed by Takeda. ASKA has already obtained exclusive commercialization right for uterine fibroids and exclusive development and commercialization rights for endometriosis for Japan of relugolix monotherapy. In January 2019, ASKA launched "Relumina$^{®}$ Tablets 40mg" for the treatment of uterine fibroid-related symptoms (menorrhagia, lower abdominal pain, lower back pain, and anemia).

Based on this agreement, ASKA will pay royalties on sales for Takeda, instead of obtaining exclusive development and commercialization for uterine fibroids for Japan. Further details regarding the agreement are not disclosed.

Uterine fibroids are benign tumors associated with menorrhagia, pain, and anemia and are known as possible causes of infertility. It often occurs in the 30s-40s, and it is reported that there are approximately 2 million women diagnosed with uterine fibroids in Japan. ASKA supports women's health, and relugolix combination tablet is considered to offer a new option for the treatment of uterine fibroids.

The impact of this agreement on consolidated results for FY 2021 will be minor.

Media Contacts
ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp